Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 776 - 800 of 14692 in total

Denosumab

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … [A263071] Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of ... 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. ... It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization …

Bisoxatin

Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine . It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.
Approved
Matched Description: … Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions ... It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and …
Matched Categories: … Alimentary Tract and Metabolism …

Atezolizumab

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted...
Approved
Investigational
Matched Description: … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Durvalumab

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and ... L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Avelumab

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … ] and Health Canada,[L48171] respectively. ... programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and ... [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126 …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Ibrutinib

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in...
Approved
Matched Description: … It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies ... [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 ... [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Valdecoxib

Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Approved
Investigational
Withdrawn
Matched Description: … ., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke …
Matched Categories: … Genito Urinary System and Sex Hormones ... Antiinflammatory and Antirheumatic Products ... Gynecological Antiinfectives and Antiseptics ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Drotaverine

Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and...
Approved
Investigational
Matched Description: … [A7036] It also has been investigated in dysmenorrhea, abortion, [A231609] and augmentation of labour ... recently, drotaverine gained attention in the treatment of benign prostatic hyperplasia, parainfluenza, and ... symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and …
Matched Categories: … Alimentary Tract and Metabolism ... Papaverine and Derivatives …

Technetium Tc-99m nofetumomab merpentan

Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10. The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues.[FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma...
Approved
Withdrawn
Matched Description: … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14 ... NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Vespula maculifrons venom protein

Vespula maculifrons venom protein is an extract of Vespula maculifrons venom. Vespula maculifrons venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Silver nitrate

Silver nitrate is an inorganic compound with the chemical formula AgNO3. In its solid form, silver nitrate is coordinated in a trigonal planar arrangement. It is often used as a precursor to other silver-containing compounds. It is used in making photographic films, and in laboratory setting as a staining agent...
Approved
Investigational
Matched Description: … in PAGE gels and in scanning electron microscopy. ... It is used in making photographic films, and in laboratory setting as a staining agent in protein visualization …
Matched Categories: … Antiseptics and Disinfectants …

Piperaquine

Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China . Its use declined in the 1980's as piperaquine resistant strains of Plasmodium falciparum appeared and artemisinin derivatives became available. It has come back into use in combination with the artemisinin derivative DB11638 as part of...
Approved
Experimental
Investigational
Matched Description: … Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China [A31550 ... Its use declined in the 1980's as piperaquine resistant strains of *Plasmodium falciparum* appeared and …
Matched Categories: … artenimol and piperaquine ... arterolane and piperaquine ... artemisinin and piperaquine ... Antiparasitic Products, Insecticides and Repellents …

Turoctocog alfa pegol

Turoctocog alfa pegol is a pegylated version of turoctocog alfa. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019. Fundamentally, the N8-GP moiety is identical to turoctocog alfa, a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made...
Approved
Matched Description: … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104]. ... The essential difference between turoctocog alfa and N8-GP, however, is the specific attachment of a ... rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Givosiran

Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States ... genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and ... non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Rezafungin

Rezafungin is an echinocandin antifungal drug.[A258393,L45633] Unlike other echinocandins such as caspofungin and micafungin, rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high plasma exposure. Rezafungin has a half-life higher than 130 hours and can be administered once a week...
Approved
Investigational
Matched Description: … _Candida tropicalis_, as well as other _Candida_ and _Aspergillus_ spp. ... Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily ... pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Dimethyl sulfoxide

A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during cryopreservation. Dimethyl sulfoxide shows a range of pharmacological activity including...
Approved
Vet approved
Matched Description: … Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation …
Matched Categories: … Genito Urinary System and Sex Hormones ... Topical Products for Joint and Muscular Pain …

Cyproheptadine

Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome.
Approved
Matched Description: … Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. ... treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and …

Bevacizumab

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer...
Approved
Investigational
Matched Description: … [A193272,A193275] It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and ... of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and ... [A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Padeliporfin

Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a focal treatment for localized prostate cancer. It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland. Padeliporfin...
Approved
Experimental
Matched Description: … Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Milk thistle

Milk thistle is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Approved
Experimental
Investigational
Matched Categories: … Herbs and Natural Products …

Celiprolol

Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina ... It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 …

Fexinidazole

Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by T. brucei gambiense and T. brucei rhodesiense, remains a moderate risk (>1/10,000 inhabitants per year in endemic areas) despite focussed control efforts. Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first...
Approved
Investigational
Matched Description: … trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by _T. brucei gambiense_ and ... [nifurtimox]/[eflornithine] combination therapy (NECT), though [melarsoprol] is highly toxic and each ... meningoencephalitic) stage in which patients experience progressively worsening neurological symptoms and …
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …

Propantheline

A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.
Approved
Matched Description: … A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment …
Matched Categories: … Alimentary Tract and Metabolism ... propantheline and psycholeptics …

Azacitidine

Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it...
Approved
Investigational
Matched Description: … As an analogue of cytidine, it is able to incorporate into RNA and DNA, disrupting RNA metabolism and ... inhibiting protein and DNA synthesis. ... [A1407] Due to its anti-neoplastic activity and its ability to inhibit methylation in replicating DNA …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …

Oxeladin

Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.
Approved
Withdrawn
Matched Description: … Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity. …
Matched Categories: … Cough and Cold Preparations …
Displaying drugs 776 - 800 of 14692 in total